← Back to Search

Antibody-Drug Conjugate

Enfortumab Vedotin for Bladder Cancer (EV-103 Trial)

Phase 1 & 2
Waitlist Available
Research Sponsored by Astellas Pharma Global Development, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Cohort-specific eligibility: Cohort J, H, and L: No prior systemic treatment, chemoradiation, or radiation therapy for MIBC. May have received prior intravesical Bacillus Calmette-Guerin (BCG) or intravesical chemotherapy for non-MIBC; Cohort J: Eligible for pembrolizumab
Eligible for pembrolizumab (Dose-escalation cohorts, Cohorts A, B, G and K Combination Arm)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

EV-103 Trial Summary

This trial will test an experimental drug, enfortumab vedotin, either alone or in combination with other cancer treatments. Pembrolizumab is a checkpoint inhibitor that is used to treat patients with urothelial cancer--a type of cancer that includes bladder, renal pelvis, ureter, or urethra cancer. The study will examine the side effects of enfortumab vedotin and measure if the cancer shrinks with different treatment combinations.

Who is the study for?
This trial is for adults with advanced or muscle-invasive urothelial cancer, including bladder and other urinary cancers. Participants should be eligible for certain chemotherapy drugs like cisplatin or carboplatin, and some may also qualify for pembrolizumab treatment. They must not have received specific prior treatments, have a good performance status (able to carry out daily activities), and an expected lifespan of at least 3 months.Check my eligibility
What is being tested?
The study tests enfortumab vedotin alone or combined with anticancer therapies such as pembrolizumab, cisplatin, carboplatin, and gemcitabine. It aims to see if these treatments can shrink the cancer in patients with locally advanced or metastatic urothelial cancer as well as those with muscle-invasive bladder cancer.See study design
What are the potential side effects?
Possible side effects include reactions related to the immune system affecting organs, infusion-related reactions from the drug entering the body, fatigue, digestive issues like nausea or diarrhea, blood disorders that affect cell counts and increase infection risk.

EV-103 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
If you are in Cohort J, H, or L, you have not received certain types of treatments for MIBC, but may have had specific bladder treatments in the past. If you are in Cohort J, you may be eligible for pembrolizumab.
Select...
I am eligible for pembrolizumab treatment.
Select...
I can't have cisplatin and haven't been treated for advanced bladder cancer, or my cancer got worse after platinum treatment.
Select...
I can care for myself, but my daily activities might be limited. My blood count and kidney function are within required levels, and I don't have severe heart failure.
Select...
My cancer got worse or came back after treatment with a platinum-based drug.
Select...
I can't have platinum-based chemo but can take gemcitabine for my urinary cancer.
Select...
I am eligible for platinum-based chemotherapy and haven't had it or any similar treatment in the last year.
Select...
I can't have cisplatin due to kidney issues, hearing loss, heart failure, or my physical condition.
Select...
My bladder cancer is mostly urothelial and has not spread beyond nearby lymph nodes.
Select...
My tumor sample from a recent bladder surgery is available for review.
Select...
I am eligible for cisplatin chemotherapy and haven't had platinum-based treatment in the last year.
Select...
I can't have cisplatin but can have carboplatin, and haven't had treatments for my bladder cancer or platinum-based therapy in the last year.
Select...
My cancer is advanced or has spread and is in the urinary system.
Select...
I can take care of myself and am up and about more than half of my waking hours.
Select...
My bladder cancer diagnosis was confirmed through tissue examination.
Select...
I cannot receive cisplatin as a treatment.
Select...
I have muscle invasive bladder cancer.
Select...
I can't have cisplatin-based chemotherapy and haven't been treated for locally advanced/metastatic urothelial cancer.
Select...
I am considered a candidate for bladder removal surgery.

EV-103 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) (Cohort K only)
Pathological complete response (pCR) rate per central pathology review (MIBC cohorts only)
Type, incidence, and severity of laboratory abnormalities (Dose escalation and Expansion Parts 1 to 3 cohorts only)
+1 more
Secondary outcome measures
Confirmed ORR by BICR according to RECIST 1.1 (Dose escalation and Cohort A only)
Confirmed ORR by investigator assessment according to RECIST 1.1 (la/mUC cohorts only)
Confirmed ORR by investigator assessment per the modified RECIST 1.1 for immune-based therapeutics (iRECIST) (Dose escalation and Part 1-3 cohorts with pembrolizumab only)
+29 more

EV-103 Trial Design

12Treatment groups
Experimental Treatment
Group I: Randomized Cohort K: Enfortumab Vedotin MonotherapyExperimental Treatment1 Intervention
Enfortumab vedotin on days 1 and 8 every 21 days
Group II: Randomized Cohort K: Enfortumab Vedotin + PembrolizumabExperimental Treatment2 Interventions
Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
Group III: Optional Cohort J:EV+Pembrolizumab in MIBC neoadjuvant settingExperimental Treatment2 Interventions
Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
Group IV: Optional Cohort F: Enfortumab Vedotin+Gemcitabine in 1L and 2LExperimental Treatment2 Interventions
Enfortumab vedotin and gemcitabine on days 1 and 8 every 21 days
Group V: Optional Cohort B: Enfortumab Vedotin + Pembrolizumab in 2LExperimental Treatment2 Interventions
Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
Group VI: EV + Pembrolizumab in cisplatin-ineligible 1L and in 2LExperimental Treatment2 Interventions
Dose Escalation: Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
Group VII: Cohort L: Enfortumab vedotin in MIBC in perioperative settingExperimental Treatment1 Intervention
Enfortumab vedotin on days 1 and 8 and every 21 days
Group VIII: Cohort H: Enfortumab vedotin in MIBC neoadjuvant settingExperimental Treatment1 Intervention
Enfortumab vedotin on days 1 and 8 every 21 days
Group IX: Cohort G: Enfortumab Vedotin + Platinum + Pembrolizumab in 1LExperimental Treatment4 Interventions
Enfortumab vedotin on days 1 and 8 plus cisplatin or carboplatin on day 1 plus pembrolizumab on day 1 every 21 days
Group X: Cohort E: Enfortumab Vedotin + Carboplatin in 1LExperimental Treatment2 Interventions
Enfortumab vedotin on days 1 and 8 plus carboplatin on day 1 every 21 days
Group XI: Cohort D: Enfortumab Vedotin + Cisplatin in 1LExperimental Treatment2 Interventions
Enfortumab vedotin on days 1 and 8 plus cisplatin on day 1 every 21 days
Group XII: Cohort A: EV + Pembrolizumab in cisplatin-ineligible 1LExperimental Treatment2 Interventions
Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
pembrolizumab
2018
Completed Phase 3
~6240
cisplatin
1997
Completed Phase 3
~3290
carboplatin
2010
Completed Phase 3
~4790
gemcitabine
2013
Completed Phase 3
~3530

Find a Location

Who is running the clinical trial?

Astellas Pharma Global Development, Inc.Lead Sponsor
192 Previous Clinical Trials
120,679 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,862 Previous Clinical Trials
5,049,352 Total Patients Enrolled
Seagen Inc.Industry Sponsor
206 Previous Clinical Trials
68,991 Total Patients Enrolled

Media Library

Enfortumab Vedotin (Antibody-Drug Conjugate) Clinical Trial Eligibility Overview. Trial Name: NCT03288545 — Phase 1 & 2
Bladder Cancer Research Study Groups: Randomized Cohort K: Enfortumab Vedotin Monotherapy, Cohort L: Enfortumab vedotin in MIBC in perioperative setting, Optional Cohort J:EV+Pembrolizumab in MIBC neoadjuvant setting, Cohort H: Enfortumab vedotin in MIBC neoadjuvant setting, Randomized Cohort K: Enfortumab Vedotin + Pembrolizumab, Cohort D: Enfortumab Vedotin + Cisplatin in 1L, Cohort E: Enfortumab Vedotin + Carboplatin in 1L, Optional Cohort F: Enfortumab Vedotin+Gemcitabine in 1L and 2L, Cohort G: Enfortumab Vedotin + Platinum + Pembrolizumab in 1L, EV + Pembrolizumab in cisplatin-ineligible 1L and in 2L, Cohort A: EV + Pembrolizumab in cisplatin-ineligible 1L, Optional Cohort B: Enfortumab Vedotin + Pembrolizumab in 2L
Bladder Cancer Clinical Trial 2023: Enfortumab Vedotin Highlights & Side Effects. Trial Name: NCT03288545 — Phase 1 & 2
Enfortumab Vedotin (Antibody-Drug Conjugate) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03288545 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What types of cancer does enfortumab vedotin (EV) commonly target?

"EV has shown to be an effective treatment against lymphoma and non-hodgkin. Additionally, it can also help treat other conditions such as malignant melanoma of skin, recurrent cervical cancer, refractory, relapsed mediastinal large b-cell lymphoma."

Answered by AI

What goals does this experiment hope to realize?

"The primary purpose of this trial, which will be conducted over a period of approximately 3 years, is to evaluate the confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR). Secondary outcomes include Pathologic downstaging (pDS) rate by central pathology review (MIBC cohorts only), PK parameter for MMAE: Tmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only), and DOR by BICR according to RECIST 1."

Answered by AI

Are participants being accepted into the trial at this time?

"That is accurate. The listing on clinicaltrials.gov affirms that this trial, which was originally published on October 11th 2017, is still recruiting patients. 467 people are needed for the study and it is being hosted at 88 different facilities."

Answered by AI

What other treatments has EV been tested against in the past?

"EV was first studied in 1997 and there are now 2449 completed studies. 2270 trials are still active, with several of them based in Milwaukee, Wisconsin."

Answered by AI

At how many different sites is this trial being conducted?

"So far, 88 patients have enrolled at locations like the Medical College of Wisconsin (Milwaukee), the Medical University of South carolina/Hollings Cancer Center in Charleston, and Weill Cornell Medical College in New york. There are also 88 other sites where people can enroll."

Answered by AI
~104 spots leftby Dec 2026